🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/12/1995 | 9,25 | 9,38 | 8,75 | 9,13 | +1,39% | 6,76% | 125.800 |
| 14/12/1995 | 10,00 | 10,00 | 8,88 | 9,00 | -8,86% | 11,25% | 154.400 |
| 13/12/1995 | 9,63 | 9,88 | 9,63 | 9,88 | +2,60% | 2,60% | 56.800 |
| 12/12/1995 | 9,88 | 10,00 | 9,63 | 9,63 | +0,00% | 3,80% | 124.000 |
| 11/12/1995 | 9,63 | 9,88 | 9,63 | 9,63 | +0,00% | 2,60% | 500.800 |
| 08/12/1995 | 10,00 | 10,00 | 9,63 | 9,63 | -3,75% | 3,75% | 49.400 |
| 07/12/1995 | 9,88 | 10,25 | 9,63 | 10,00 | -2,44% | 6,33% | 141.000 |
| 06/12/1995 | 10,50 | 10,50 | 10,00 | 10,25 | -2,38% | 4,76% | 49.000 |
| 05/12/1995 | 10,63 | 10,63 | 10,31 | 10,50 | -1,18% | 2,94% | 96.000 |
| 04/12/1995 | 10,63 | 10,63 | 10,25 | 10,63 | +1,19% | 3,53% | 48.400 |
| 01/12/1995 | 10,00 | 10,75 | 10,00 | 10,50 | +1,82% | 7,50% | 194.000 |
| 30/11/1995 | 10,38 | 10,38 | 10,00 | 10,31 | -0,60% | 3,61% | 90.000 |
| 29/11/1995 | 10,06 | 10,38 | 9,88 | 10,38 | +6,41% | 4,97% | 279.000 |
| 28/11/1995 | 10,25 | 10,25 | 9,75 | 9,75 | -4,88% | 4,88% | 14.200 |
| 27/11/1995 | 9,88 | 10,25 | 9,69 | 10,25 | +5,81% | 5,70% | 75.400 |
| 24/11/1995 | 9,75 | 9,75 | 9,50 | 9,69 | +1,97% | 2,56% | 59.600 |
| 22/11/1995 | 9,75 | 9,75 | 9,50 | 9,50 | -0,65% | 2,56% | 30.400 |
| 21/11/1995 | 10,00 | 10,00 | 9,50 | 9,56 | -2,55% | 5,00% | 144.200 |
| 20/11/1995 | 10,38 | 10,75 | 9,75 | 9,81 | -4,27% | 9,64% | 318.800 |
| 17/11/1995 | 10,00 | 10,25 | 10,00 | 10,25 | +1,23% | 2,50% | 138.800 |
| 16/11/1995 | 9,75 | 10,25 | 9,75 | 10,13 | +2,53% | 5,13% | 364.600 |
| 15/11/1995 | 9,88 | 9,88 | 9,50 | 9,88 | +1,94% | 3,80% | 43.600 |
| 14/11/1995 | 9,75 | 9,88 | 9,50 | 9,69 | +0,65% | 3,85% | 44.200 |
| 13/11/1995 | 9,63 | 9,75 | 9,38 | 9,63 | +1,32% | 3,90% | 67.200 |
| 10/11/1995 | 9,75 | 10,00 | 9,25 | 9,50 | -5,00% | 7,69% | 123.600 |
| 09/11/1995 | 10,00 | 10,13 | 9,63 | 10,00 | +1,27% | 5,00% | 165.800 |
| 08/11/1995 | 9,25 | 10,13 | 9,00 | 9,88 | +6,76% | 12,16% | 408.600 |
| 07/11/1995 | 8,88 | 9,25 | 8,50 | 9,25 | +5,71% | 8,45% | 353.000 |
| 06/11/1995 | 8,38 | 8,75 | 8,19 | 8,75 | +5,26% | 6,72% | 721.200 |
| 03/11/1995 | 8,38 | 8,38 | 8,13 | 8,31 | +1,92% | 2,99% | 113.600 |